Extended frontalis orbicularis oculi muscle flap shortening for treating refractory apraxia of eyelid opening associated with blepharospasm.
Journal
Journal of the Chinese Medical Association : JCMA
ISSN: 1728-7731
Titre abrégé: J Chin Med Assoc
Pays: Netherlands
ID NLM: 101174817
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
6
10
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
Refractory apraxia of eyelid opening (AEO) is mostly unresponsive to botulinum toxin (BTx) and inevitably leads to functional blindness. To treat this challenging condition, an innovative surgical technique was proposed. The extended frontalis orbicularis oculi muscle (FOOM) flap shortening consisting of frontalis suspension, partial myectomy, and myotomy in situ of eyelid protractors was applied to treat refractory AEO associated with blepharospasm. The postoperative outcomes and patient satisfaction were evaluated. Seven patients (mean ages 64.1 ± 3.9 years) of 14 eyelids in total had an average flap shortening distance of 24.4 ± 1.3 mm. During a mean follow-up of 31.6 ± 11.4 months, the average BTx dosage reduced from 58.6 ± 12. 1 units to 30.0 ± 8.2 units, with a mean injection interval decreasing from 2.3 ± 0.5 months to 4.1 ± 0.9 months (p < 0.05). Palpebral fissure height increased from 1.4 ± 0.5 mm to 7.9 ± 0.7 mm, and the disability scale decreased from 78.8% ± 7.2% to 12.6% ± 7.0% (p < 0.05). The postoperative BTx dosage and frequency were significantly reduced. All patients restored voluntary eyelid opening and reported high postoperative satisfaction (average Likert scale 4.6 ± 0.5). Extended FOOM flap shortening is an effective treatment to solve refractory AEO associated with blepharospasm.
Sections du résumé
BACKGROUND
Refractory apraxia of eyelid opening (AEO) is mostly unresponsive to botulinum toxin (BTx) and inevitably leads to functional blindness. To treat this challenging condition, an innovative surgical technique was proposed.
METHODS
The extended frontalis orbicularis oculi muscle (FOOM) flap shortening consisting of frontalis suspension, partial myectomy, and myotomy in situ of eyelid protractors was applied to treat refractory AEO associated with blepharospasm. The postoperative outcomes and patient satisfaction were evaluated.
RESULTS
Seven patients (mean ages 64.1 ± 3.9 years) of 14 eyelids in total had an average flap shortening distance of 24.4 ± 1.3 mm. During a mean follow-up of 31.6 ± 11.4 months, the average BTx dosage reduced from 58.6 ± 12. 1 units to 30.0 ± 8.2 units, with a mean injection interval decreasing from 2.3 ± 0.5 months to 4.1 ± 0.9 months (p < 0.05). Palpebral fissure height increased from 1.4 ± 0.5 mm to 7.9 ± 0.7 mm, and the disability scale decreased from 78.8% ± 7.2% to 12.6% ± 7.0% (p < 0.05). The postoperative BTx dosage and frequency were significantly reduced. All patients restored voluntary eyelid opening and reported high postoperative satisfaction (average Likert scale 4.6 ± 0.5).
CONCLUSION
Extended FOOM flap shortening is an effective treatment to solve refractory AEO associated with blepharospasm.
Identifiants
pubmed: 37796444
doi: 10.1097/JCMA.0000000000000979
pii: 02118582-202310000-00012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
935-939Informations de copyright
Copyright © 2023, the Chinese Medical Association.
Déclaration de conflit d'intérêts
Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
Références
Rocha Cabrero F, De Jesus O. Apraxia of lid opening. Treasure Island, FL: StatPearls Publishing LLC; 2022.
Weiss D, Wächter T, Breit S, Jacob SN, Pomper JK, Asmus F, et al. Involuntary eyelid closure after STN-DBS: evidence for different pathophysiological entities. J Neurol Neurosurg Psychiatry 2010;81:1002–7.
Comoglu S, Kocer B, Kertmen H, Onder H. The detailed investigation of eyelid-opening apraxia after subthalamic nucleus deep brain stimulation. Ann Indian Acad Neurol 2022;25:775–6.
Jiang W, Gan L, Sun Y, Dong M, Yu P. Apraxia of eyelid opening secondary to possible progressive supranuclear palsy: a case report. Int J Neurosci 2021;131:708–10.
Kataoka H, Sawada Y, Shimozato N, Inatomi S, Iguchi N, Yoshiji H, et al. Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment. Clin Park Relat Disord 2020;3:100073.
Ou H, Tzeng NS, Chang HA. Clozapine combined with long-acting Iinjectable antipsychotic agents-induced apraxia of eyelid opening. Am J Ther 2022;29:e676–7.
Kohsaka M, Oeda T, Umemura A, Tomita S, Park K, Yamamoto K, et al. Oxybuprocaine for apraxia of lid opening in Parkinson’s disease: a placebo-controlled pilot trial. Mov Disord 2018;33:494–5.
Rana AQ, Kabir A, Dogu O, Patel A, Khondker S. Prevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremor. Eur Neurol 2012;68:318–21.
Boghen D. Apraxia of lid opening: a review. Neurology 1997;48:1491–4.
Tawfik HA, Dutton JJ. Debunking the puzzle of eyelid apraxia: the muscle of Riolan hypothesis. Ophthalmic Plast Reconstr Surg 2023;39:211–20.
Reggie SN, Chen JJ, Lee MS, Chung SM. Sleep-induced apraxia of eyelid opening. J Neuroophthalmol 2017;37:390–2.
Jain S, Walsh RD. Co-occurrence of two rare sleep-related neuro-ophthalmologic phenomena: transient monocular vision loss on awakening and sleep-induced apraxia of eyelid opening (awakening ptosis). J Neuroophthalmol Doi:10.1097/WNO.0000000000001662.
doi: 10.1097/WNO.0000000000001662
Romito LM, Albanese A. Dopaminergic therapy and subthalamic stimulation in Parkinson’s disease: a review of 5-year reports. J Neurol 2010;257(Suppl 2):S298–304.
Jordan DR, Anderson RL, Digre KB. Apraxia of lid opening in blepharospasm. Ophthalmic Surg 1990;21:331–4.
Lamberti P, De Mari M, Zenzola A, Aniello MS, Defazio G. Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders. Neurol Sci 2002;23(Suppl 2):S81–2.
Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthalmic Plast Reconstr Surg 1998;14:305–17.
Georgescu D, Vagefi MR, McMullan TF, McCann JD, Anderson RL. Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening. Am J Ophthalmol 2008;145:541–7.
Lai HT, Chen AD, Lee SS, Lin YH, Lai CS. Myotomy in situ for essential blepharospasm refractory to botulinum toxin. Ann Plast Surg 2020;84:S74–9.
Gillum WN, Anderson RL. Blepharospasm surgery. An anatomical approach. Arch Ophthalmol 1981;99:1056–62.
McCord CD Jr, Coles WH, Shore JW, Spector R, Putnam JR. Treatment of essential blepharospasm. I. Comparison of facial nerve avulsion and eyebrow-eyelid muscle stripping procedure. Arch Ophthalmol 1984;102:266–8.
Kennedy RH, Waller RR, Henderson JW, Kesty KR. Management of blepharospasm. Ophthalmic Plast Reconstr Surg 1985;1:253–61.
Garland PE, Patrinely JR, Anderson RL. Hemifacial spasm. Results of unilateral myectomy. Ophthalmology 1987;94:288–94.
Bates AK, Halliday BL, Bailey CS, Collin JR, Bird AC. Surgical management of essential blepharospasm. Br J Ophthalmol 1991;75:487–90.
Chapman KL, Bartley GB, Waller RR, Hodge DO. Follow-up of patients with essential blepharospasm who underwent eyelid protractor myectomy at the Mayo Clinic from 1980 through 1995. Ophthalmic Plast Reconstr Surg 1999;15:106–10.
Frueh BR, Musch DC, Bersani TA. Effects of eyelid protractor excision for the treatment of benign essential blepharospasm. Am J Ophthalmol 1992;113:681–6.
Yen MT, Anderson RL, Small RG. Orbicularis oculi muscle graft augmentation after protractor myectomy in blepharospasm. Ophthalmic Plast Reconstr Surg 2003;19:287–96.
Pariseau B, Worley MW, Anderson RL. Myectomy for blepharospasm 2013. Curr Opin Ophthalmol 2013;24:488–93.
Kent TL, Petris CK, Holds JB. Effect of upper eyelid myectomy on subsequent chemodenervation in the management of benign essential blepharospasm. Ophthalmic Plast Reconstr Surg 2015;31:222–6.
Clark J, Randolph J, Sokol JA, Moore NA, Lee HBH, Nunery WR. Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm. Digit J Ophthalmol 2017;23:8–12.
Patel BC. Surgical management of essential blepharospasm. Otolaryngol Clin North Am 2005;38:1075–98.
De Groot V, De Wilde F, Smet L, Tassignon MJ. Frontalis suspension combined with blepharoplasty as an effective treatment for blepharospasm associated with apraxia of eyelid opening. Ophthalmic Plast Reconstr Surg 2000;16:34–8.
Karapantzou C, Dressler D, Rohrbach S, Laskawi R. Frontalis suspension surgery to treat patients with essential blepharospasm and apraxia of eyelid opening-technique and results. Head Face Med 2014;10:44.
Dressler D, Karapantzou C, Rohrbach S, Schneider S, Laskawi R. Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results. J Neural Transm (Vienna) 2017;124:253–7.
Sweeney AR, Dermarkarian CR, Williams KJ, Allen RC, Yen MT. Polytetrafluoroethylene frontalis suspension in blepharospasm with eyelid apraxia: an effective and well-tolerated adjunct to botulinum toxin therapy. Orbit 2021;40:39–43.
Lai CS, Chang KP, Lai CH, Huang SH, Tsai CC, Lin SD. A dynamic technique for the treatment of severe or recurrent blepharoptosis: frontalis-orbicularis oculi muscle flap shortening. Ophthalmologica 2009;223:376–82.
Lai CS, Lai CH, Huang SH, Sun IF, Chang KP, Lee SS, et al. A new trend for the treatment of blepharoptosis: frontalis-orbicularis oculi muscle flap shortening technique. J Plast Reconstr Aesthet Surg 2010;63:233–9.
Lai CS, Chang KP, Lee SS, Hsieh TY, Lai HT, Huang YH, et al. The role of frontalis orbicularis oculi muscle flap for correction of blepharoptosis with poor levator function. Ann Plast Surg 2013;71(Suppl 1):S29–36.
Roggenkämper P, Nüssgens Z. Frontalis suspension for essential blepharospasm unresponsive to botulinum toxin therapy. First results. Ger J Ophthalmol 1993;2:426–8.
Grivet D, Robert PY, Thuret G, De Féligonde OP, Gain P, Maugery J, et al. Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients. Ophthalmic Plast Reconstr Surg 2005;21:230–4.
Kerty E, Eidal K. Apraxia of eyelid opening: clinical features and therapy. Eur J Ophthalmol 2006;16:204–8.
Nicoletti AG, Pereira IC, Matayoshi S. Browlifting as an alternative procedure for apraxia of eyelid opening. Ophthalmic Plast Reconstr Surg 2009;25:46–7.
Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2000;2:393–400.
Rana AQ, Shah R. Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment. Acta Neurol Belg 2012;112:95–6.
Tozlovanu V, Forget R, Iancu A, Boghen D. Prolonged orbicularis oculi activity: a major factor in apraxia of lid opening. Neurology 2001;57:1013–8.
Park DH, Ahn KY, Han DG, Baik BS. Blepharoptosis repair by selective use of superiorly based muscle flaps. Plast Reconstr Surg 1998;101:592–603.
Lai CS, Lai YW, Huang SH, Lee SS, Chang KP, Chen AD. Surgical correction of the intractable blepharoptosis in patients with ocular myasthenia gravis. Ann Plast Surg 2016;76(Suppl 1):S55–9.
Huang SH, Lee CC, Lai HT, Takahashi H, Wang YC, Lai CS. The function-preserving frontalis orbicularis oculi muscle flap for the correction of severe blepharoptosis with poor levator function. Aesthet Surg J 2021;41:NP260–6.